Table 2 Per-protocol secondary endpoint analysis of treatment responses in cases with Plasmodium falciparum or Plasmodium vivax for PCR-uncorrected malaria
AL | DHA-PPQ | Total | P-value | |
|---|---|---|---|---|
P. falciparum assessed at day 28, n | 110 | 138 | 248 | |
Adequate clinical and parasitological response, n (%) [95% CI] | 108 (98.2) [92.9–99.7] | 138 (100) [96.6–100] | 246 (99.2) | − 0.28 |
Early treatment failure, % | 0 | 0 | 0 | – |
Late clinical failure, % | 0.9 | 0 | 0.4 | – |
Late parasitological failure, % | 0.9 | 0 | 0.4 | – |
P. falciparum assessed at day 42, n | 106 | 135 | 241 | |
Adequate clinical and parasitological response, n (%) [95% CI] | 102 (96.2) [90.07–98.8] | 132 (97.8) [93.2–99.4] | 234 (97.1) | 0.48 |
Early treatment failure, % | 0 | 0 | 0 | – |
Late clinical failure, % | 0 | 0 | 0 | – |
Late parasitological failure, % | 3.8 | 2.2 | 2.9 | – |
P. vivax assessed day 28, n | 23 | 41 | 64 | |
Adequate clinical and parasitological response, n (%) [95% CI] | 20 (87.0) [65.3–96.6] | 41 (100) [89.3–100] | 61 (95.3) | 0.06 |
Early treatment failure, % | 0 | 0 | 0 | – |
Late clinical failure, % | 4.3 | 0 | 1.6 | – |
Late parasitological failure, % | 8.7 | 0 | 3.1 | – |
P. vivax assessed day 42, n | 19 | 39 | 58 | |
Adequate clinical and parasitological response, n (%) [95% CI] | 13 (68.4) [43.5–86.4] | 34 (87.2) [71.8–95.2] | 47 (81.03) | 0.23 |
Early treatment failure, % | 0 | 0 | 0 | – |
Late clinical failure, % | 10.5 | 5.1 | 6.9 | – |
Late parasitological failure, % | 21.1 | 7.7 | 5.3 | – |